Moxian, Inc. (NASDAQ: MOXC) Ready for a 75% Upside Ride?

• Crystal Equity Research maintains $5.25 price target for Moxian
• 75% upside from current price
• Price appreciation could be even higher depending on paid user conversions

Crystal Equity Research published a research report on Moxian, Inc. (NASDAQ: MOXC) in January 2017 and identified a price target of $5.25 for the company. The price target remained unchanged at $5.25 in the August 15 updated report from Crystal Equity, and the report categorized an investment in Moxian as a speculative buy (http://dtn.fm/AmU79). Currently trading near $3.00 per share, reaching the research projection would equate to a 75 percent upside ride for Moxian. That’s the kind of speculative return sought by most investors.

The Crystal Equity Research report highlighted areas of Moxian’s business that could be catalysts for even greater price appreciation. The report cites the company’s memorandum of understanding with Shewn International Group in Shanghai aimed at a joint venture featuring Shewn’s fine wine clubs and using Moxian+ online-to-offline technology. This proposed joint venture with Shewn is an example of a change in market penetration tactics by Moxian, emphasizing pacts with enterprises needing Moxian+ platform payments or any of the unique CRM features created by Moxian. Moxian would earn fees based on a percentage of digital payments traffic by Shewn customers on the Moxian+ platform.

Moxian, Inc. caters to and focuses on the new Chinese consumer and, importantly, bridges e-commerce to brick-and-mortar retail. Moxian provides small- and medium-sized brick-and-mortar businesses with cutting-edge turnkey solutions to attract and maintain customers. Free to the consumer, Moxian’s creative and socially interactive online platforms and mobile applications are moving the burgeoning Chinese consumer from online views to retail purchases at Moxian’s brick-and-mortar retail client locations. Moxian’s seductive social network integrates social media and business into a single platform that offers products, features and services that appeal to consumers, keeping them engaged and referring new customers.

The company’s ingenious online platforms and mobile applications, the Moxian+ User app and the Moxian+ Business app, allow businesses to interface with both new and existing customers. These online interactions provide each business the data to analyze consumer likes, dislikes and trends, providing Moxian’s business customers with invaluable consumer information and a real-time, state-of –the-art CRM. Moxian is in the midst of converting its unpaid platforms to paid, reflected in its joint venture with upscale wine distributor Shewn. This conversion could significantly enhance Crystal Equity’s price target.

One line on the home page of Crystal Equity Research’s website says, “INSIGHT FOR ALPHA RETURNS”. Crystal has set and maintained a target of $5.25 on shares of Moxian, representing a 75 percent upside from the current price. If the conversion to paid users goes as planned, alpha returns could be in the bank.

For more information, visit the company’s website at www.Moxian.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

India Globalization Capital, Inc. (NYSE: IGC) Growth Potential Fueled by Phytocannabinoid Treatments

• Hyalolex for Alzheimer’s and other cannabis-based drugs for pain, epilepsy, and more are raising the market valuation growth potential for IGC
• Phytocannabinoids target protein receptors in the brain, peripheral nervous system and other parts of the body, including the lungs, liver, and other organs
• Cannabidiol makes up as much as 40 percent of cannabis-plant extract and has more potential medical uses than THC

Cannabinoid receptors have been known in the medical community since 1988. India Globalization Capital, Inc. (NYSE MKT: IGC) is the first company to develop revolutionary cannabis-based pharmaceuticals targeting Alzheimer’s. Based on this alone, the company’s market valuation growth potential is high, given the possibilities now recognized for these compounds. IGC has a deep pipeline of products, including recently announced therapies such as IGC-501, for arthritic and neuropathic pain; IGC-502 for canine seizures; and IGC-504 for cachexia, a syndrome often associated with debilitating diseases such as multiple sclerosis, Parkinson’s and cancer.

The potential for growth is strong, as cannabis companies such as Anavex Life Sciences Corp. (NASDAQ: AVXL), AC Immune Ltd. (NASDAQ: ACIU) and others have seen market valuations in the hundreds of millions of dollars and even higher.

While there is no cure for Alzhimer’s, therapies, such as the one IGC is pursuing for Alzheimer’s, hold promise in addressing the disease. Phytocannabinoid treatments are also effective because of the protein receptors in the brain and other tissues of the body. There are several different types; one includes the G protein-coupled receptor family, activated by endocannabinoids the body synthesizes when under stress. These receptors play a role in pain modulation, appetite, mood, and even memory.

There are also CB1 receptors, which are thought to be expressed at the synapses in the brain. They have also been found in the peripheral nerves and in muscle, liver, and lung tissue, as well as in fat. Aside from being associated with pain regulation, these cannabinoid receptors have effects on emotion, sensory perception, memory, cognition, and movement. Some autonomous functions are affected as well. Found in the immune system, CB2 receptors have anti-inflammatory properties and other functions, being based in T cells and B cells. They have also been found in macrophages and hematopoietic cells.

Evidence suggests there are more types of cannabinoid receptors. The known types are activated naturally by endocannabinoids but can also be stimulated by compounds found in cannabis plants and by synthetic cannabinoids, which helped researchers identify the receptors in the first place.

Until recently, it was tetrahydrocannabinol that had the attention of mainstream media, known for its psychotropic effects. However, cannabidiol (CBD), which constitutes up to 40 percent of plant extracts, seems to have more medical applications. It’s widely believed to have anti-psychotic, anti-depressive, anxiety-reducing, and anti-convulsive effects. Therefore, CBD has the potential to be useful to the 50 million people around the world with refractory, or drug resistant, epilepsy; the 1.3 million individuals in the United States affected by cachexia every year; the 5.3 million people in the country with Alzheimer’s disease; and the millions who suffer from chronic pain.

For more information, visit the company’s website at www.IGCInc.us

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Net Element (NASDAQ: NETE) Maintains Listing following Meeting with Nasdaq Hearings Panel

• Nasdaq Hearings Panel grants decision on listing based on shareholder equity and minimum bid issues, conditional on NETE providing evidence of compliance by October 20, 2017
• NETE says impact of its cost cutting program should be realized by the third quarter of 2017
• Zack’s Research Report projects that NETE will generate sales of $74.6 million by FY2018

Net Element, Inc.’s (NASDAQ: NETE) common stock will continue to be traded on the Nasdaq Capital Market after the company met with the exchange’s Nasdaq Hearings Panel. The panel’s decision to grant the company’s request is conditional on NETE providing evidence of compliance with Nasdaq’s regulations by October 20, 2017, as noted by the company in a news release (http://dtn.fm/AN4sa).

NETE is a cloud-based financial company that accepts electronic payments in an omni-channel environment. The payments are processed at point-of-sale and on mobile devices. The firm also offers management tools for clients. A Zack’s Research report projected that NETE would generate $74.6 million in sales by 2018 (http://dtn.fm/6HWor).

NETE received an initial letter from Nasdaq explaining that, because the company was no longer in compliance with its regulations concerning shareholders’ equity and minimum bid price, its stock would be delisted. In a meeting afterward, NETE presented its plan for Nasdaq regulation compliance on both issues.

“We are working diligently to comply with Nasdaq’s listing requirements while improving shareholder value,” Oleg Firer, chief executive officer of NETE, stated in a news release. However, the company said there can be no assurance it will cure its stockholders’ equity or bid price deficiencies.

Nasdaq requires $2.5 million in shareholder equity. The exchange cited NETE’s shareholder equity of only $1,975,435 for the quarter ended June 30. The exchange also has a regulation requiring a $1 minimum bid.

In a July 2017 letter to shareholders, NETE said its institution of a cost cutting program should be realized by the third quarter of 2017.

For more information, visit the company’s website at www.NetElement.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Exciting Potential for Growth Fuels Net Element (NASDAQ: NETE) as E-commerce and Consumers Converge

• 2017 second quarter net revenues up 18 percent to $16.1 million
• PayOnline, a flexible e-commerce payment solutions platform, launches in U.S.
• Net Element is strategically poised for growth in the U.S. and emerging countries

Mobile-based purchasing by the world’s consumers is booming thanks to smartphones and other portable devices. Net Element (NASDAQ: NETE) is tapping into that expanding e-commerce world with its focus on small- to medium-sized businesses in the United States and select emerging markets.

Florida-based Net Element is a global financial technology company delivering a wide range of value-added solutions that support electronic payments in an omni-channel environment that spans point-of-sale, e-commerce, and mobile devices.

Its PayOnline subsidiary, launched July 2017 in the United States, supports more than 100 payment methods in as many currencies, in addition to credit card acceptance, and it is certified with most payment processors in the United States and globally.

PayOnline’s Instant Payment Module utilizes chat-bots with four popular instant messaging apps to help retailers interact with consumers, which Net Element believes represents a global opportunity for the company.

This major consumer habit of buying online, fueled by millennials, bodes well for Net Element and its long-term growth opportunities as e-commerce markets expand.

An online retail forecast from Forrester, cited by Digital Commerce 360, predicts that U.S. shoppers will splurge on nearly $460 billion in online sales in 2017, proving the global marketplace is ripe for Net Element’s ideas (http://dtn.fm/w4DoU).

“We are pleased with our continued growth. Our results are a reflection of our ability to deliver growth,” Oleg Firer, CEO of Net Element, said prior to the company’s August 15 conference call to discuss second quarter 2017 financial results and business highlights. “We are excited about our strategic initiatives for the remainder of the year as we continue to streamline international operations and reduce operating expenses while managing the strong U.S. growth and expansion.”

For more information, visit the company’s website at www.NetElement.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

India Globalization Capital, Inc. (NYSE: IGC) – The Pros are Already Picking Horses

• Alzheimer’s is America’s most expensive disease, with a new diagnosis every 66 seconds
• IGC’s unique use of marijuana extracts in combination therapy for potential Alzheimer’s breakthrough shows promise
• Low market cap could make IGC a big winner for early investors

Alzheimer’s disease is one of the greatest medical, ethical, and financial challenges facing society today. Currently, more than 5.3 million Americans and their families have to deal with Alzheimer’s disease, and projections suggest that number will nearly triple to 14 million Americans by 2050. Globally, the figures are even more staggering, with about 47 million people worldwide currently diagnosed and projections at 132 million in less than three decades. Right now, someone in America develops Alzheimer’s every 66 seconds, and soon, this deadly diagnosis is expected to occur every 33 seconds.

Alzheimer’s is already the country’s most expensive disease. In 2016 U.S. costs totaled $236 billion and global costs exceeded $600 billion. These figures will skyrocket unless scientists develop new approaches to prevent or cure this insidious disease. Given the magnitude of the problem, pharmaceutical companies are scrambling to find ways to mitigate the disease’s devastation.

With so much on the line, it’s no wonder that Wall Street has already started to place bets on who might be a winner in this race. In this vein, Goldman Sachs recently highlighted Biogen (NASDAQ: BIIB) and its lead pipeline Alzheimer’s drug as one of the first to possibly prevent or slow the progression of the disease (http://dtn.fm/QoqT5). Goldman pegged potential drug sales at over $12 billion and targeted the $60 billion market cap stock at a 17 percent premium, if successful. However, everyone knows there are no guaranteed winners in this race. A broad spectrum of options must be considered if investors want to participate in the enormous upside potential of an effective Alzheimer’s treatment.

One compelling candidate with a promising patent pending Alzheimer’s treatment protocol and ridiculously low market valuation is India Globalization Capital (NYSE MKT: IGC). IGC is a pioneer in the development of new classes of phytocannabinoid pharmaceuticals with broad therapeutic applications for both humans and animals. IGC’s pipeline of patented and patent pending therapeutics include treatments for pain, post-traumatic stress disorder, cachexia, neurologic disorders, Parkinson’s, and, now, Alzheimer’s disease.

IGC recently acquired the exclusive rights to its novel THC-based treatment for Alzheimer’s disease from the University of South Florida (http://www.igcinc.us/alzheimers-disease/). The patent identifies discovery of a new pathway in which low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is exactly what occurs in Alzheimer’s disease and causes cognitive decline.

IGC plans to enter clinical trials this year on its potential cannabis-based blockbuster treatment for Alzheimer’s, as well as on the company’s primary pipeline of other major therapeutics that address large market maladies. Any one of these trials could provide breakthrough treatments for previously untreatable disease. With a market capitalization currently around $10 million, IGC is one very interesting bet investors may want to place in this race for an effective Alzheimer’s treatment. Any positive results from the clinical trials could easily catapult valuation and make IGC a big winner for early investors.

For more information, please visit www.IGCInc.us

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Crystal Equity Research Reaffirms Price Target of $5.25 for Moxian, Inc. (NASDAQ: MOXC)

In January 2017, Crystal Equity Research LLC published an initial report on Moxian, Inc. (NASDAQ: MOXC) with a price target of $5.25, and that price target remains unchanged as of an August 15 updated report from Crystal. Crystal categorized investment in Moxian as a “speculative buy” and made positive note of the company’s joint venture with Shewn International Group in Shanghai, also stating it anticipates revising its revenue estimates for Moxian upward when the Shewn transaction is formalized. As noted in a recent NNW article:

“Moxian is an integrated platform operator in the midst of converting its unpaid platforms to paid. Its joint venture with upscale wine distributor Shewn — expected by Crystal Equity to be finalized by the end of September 2017 — calls for Shewn to use Moxian+ Merchant App technology. It uses a UnionPay module processing system and offers Moxian’s Mo-Points redemption plan. In return, Shewn offers Moxian quicker and less costly market penetration and an additional revenue stream. Moxian will earn a fee on Shewn’s digital sales processed on the Moxian+ platform. ‘Execution on the Shewn International joint venture should put greater certainty into the Moxian story, providing the foundation for greater investor confidence and a higher valuation of the shares. We view it as an important catalyst for valuation. In our view, the stock provides an interesting play on China’s e-commerce industry,’ the report said.”

To view the full article, visit http://dtn.fm/j28R8

About Moxian, Inc.

Founded in 2013 in Shenzhen, China with branch offices in Beijing, Malaysia, and Hong Kong, Moxian, Inc. is an offline-to-online (O2O) integrated platform operator. The Company’s “Moxian+” mobile App platform connects Users to Merchant Clients through games, rewards and social events that they enjoy and in return, Users provide valuable information that Merchant Clients can use to effectively promote products and services offered at their brick and mortar stores. More information about the Company can be found at www.moxian.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Net Element (NASDAQ: NETE) Faces Plentiful Growth Opportunities as US E-commerce Market Continues to Grow

The quickly growing e-commerce market in the United States provides plentiful opportunities for investment into online payment solution providers like Net Element, Inc. (NASDAQ: NETE) and its subsidiary PayOnline, a groundbreaking and flexible payment processing platform. As consumers benefit from an increasing number of channels for online ordering—driven by the marked preference of younger generations to make purchases online—the U.S. e-commerce market continues expanding, having reached approximately $395 billion in 2016. As noted in a recent NNW article:

“Mobile purchases are leading the way when it comes to the growth of the e-commerce sector, with almost half of the digital retail traffic happening on mobile, according to Business Insider data (http://dtn.fm/Udg0y). But the traffic increase does not translate into actual purchases, with consumers preferring to use desktop computers rather than their smartphones for online orders. The volume of mobile traffic, however, presents a major opportunity for retailers, as mobile allows consumers and vendors to communicate more effectively and more frequently. With the right tools and software, mobile payments could grow exponentially, helping expand the digital sales market further. This is where global financial technology group Net Element’s PayOnline platform comes in. Having just entered the U.S. e-commerce market, the PayOnline subsidiary is one of the most versatile global online payment solutions in the industry, leveraging its parent company’s experience with omni-channel electronic payments acceptance solutions that include e-commerce, point-of-sale and mobile devices.”

To view the full article, visit http://dtn.fm/zuVF4

About Net Element

Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the US and selected emerging markets. In the US it aims to grow transactional revenue by innovating SME productivity services such as its cloud based, restaurant and retail point-of-sale solution Aptito. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions such as UAE, Kazakhstan, Kyrgyzstan and Azerbaijan where initiatives have been recently launched. Net Element was named in 2016 by South Florida Business Journal as one of the fastest growing technology companies. Further information is available at www.netelement.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Moxian, Inc. (NASDAQ: MOXC) Price Target of $5.25 Reaffirmed by Crystal Equity Research

• Moxian praised for new joint venture strategy to help penetrate key markets in China
• Crystal Equity Research projects Moxian’s sales reaching $2.3 million in FY2018
• Moxian adding three to its board of directors, including Liu Shu Juan, CEO of Shewn International Group, Inc.

Moxian, Inc.’s (NASDAQ: MOXC) price target of $5.25 remains unchanged in the August 15, 2017, update report from Crystal Equity Research LLC (http://dtn.fm/hmV0h), which published its initial report on the company in January 2017. Crystal classified an investment in the company as a ‘speculative buy’ and made positive note of the firm’s joint venture with Shewn International Group in Shanghai. It also said it anticipates revising its revenue estimates for Moxian upward when the Shewn transaction is formalized.

Moxian is an integrated platform operator in the midst of converting its unpaid platforms to paid. Its joint venture with upscale wine distributor Shewn — expected by Crystal Equity to be finalized by the end of September 2017 — calls for Shewn to use Moxian+ Merchant App technology. It uses a UnionPay module processing system and offers Moxian’s Mo-Points redemption plan. In return, Shewn offers Moxian quicker and less costly market penetration and an additional revenue stream. Moxian will earn a fee on Shewn’s digital sales processed on the Moxian+ platform.

“Execution on the Shewn International joint venture should put greater certainty into the Moxian story, providing the foundation for greater investor confidence and a higher valuation of the shares. We view it as an important catalyst for valuation. In our view, the stock provides an interesting play on China’s e-commerce industry” the report said.

Moxian has already signed a memorandum of understanding with Shewn. The research company quoted James Mengdong Tan, CEO of Moxian, as saying that he anticipates 30-40 more joint venture possibilities in the pipeline. Crystal Equity also liked Moxian’s lower cash usage in the quarter ended June 2017, resulting from reduced SG&A costs.

According to an 8K SEC filing on August 16, 2017 (http://dtn.fm/9ho1I), Moxian also had a change in its board of directors. It added Chan Fook Meng, Dr. Yu Lin and Liu Shu Juan to the board. Liu, currently the CEO of Shewn International Group, Inc., is also financial controller of Shanghai Shewn Wine Co. Ltd., the main operating company for Shewn in China. At Moxian, Liu will also serve as Moxian’s executive director.

For more information, visit the company’s website at www.Moxian.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

India Globalization Capital’s (NYSE: IGC) Cannabis-Based Alzheimer’s Disease Treatment Increases Upside Potential

• Alzheimer’s is a leading cause of dementia in adults in the United States
• IGC’s cannabis-based drug may reverse the buildup of beta-amyloid plaque
• Hyalolex and other phytocannabinoid-based drugs are fueling potential for the company’s market valuation growth

Alzheimer’s disease is currently the sixth-leading cause of death in the nation and the most common cause of dementia in older individuals. The chronic neurodegenerative disease has had no cure or effective treatment for reducing its symptoms, but India Globalization Capital, Inc. (NYSE MKT: IGC) is seeking to change that with a potential blockbuster drug. Hyalolex, otherwise known as IGC-AD1, is a cannabis-based drug that has the potential to reduce beta-amyloid plaque buildup in the brain, with the possibility of lessening some of the symptoms of the disease. A recent article focused on the efforts of IGC and other pharmaceutical companies to develop cannabinoid-based therapies for a range of serious diseases can be found at http://dtn.fm/7OmXx.

In June 2017, the company announced its acquisition of exclusive rights, from the University of South Florida, for a tetrahydrocannabinol (THC)-based treatment. A study conducted at the university found that the cannabis extract reversed beta-amyloid accumulation in mice. Subsequently, IGC became the exclusive licensee of the patent “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” It involves a new pathway for low doses of the compound to bind to the plaque and prevent it from collecting on nerve cells (the process thought to result in cognitive decline).

Hyalolex isn’t the only pipeline drug driving the potential for IGC’s market valuation growth. Several cannabis companies have seen hundreds of millions, even billions, of dollars in market valuations with phytocannabinoid-based therapies. Plus, IGC isn’t limiting its drug development to novel Alzheimer’s treatments. Others include Serosapse, for Parkinson’s disease; Natrinol, to treat cachexia in AIDS and cancer patients; and Caesafin, a combination therapy that targets dogs and cats with seizures.

Currently, IGC is the only publicly-traded pharmaceutical cannabis stock that addresses Alzheimer’s disease. However, a number of studies suggest the therapeutic value of treating the disease with cannabis-based drugs. These include studies of how THC molecules can potentially bind to and break up amyloid-beta proteins and other analysis suggesting positive results and that patients for the most part tolerate the effects of THC. A study on mice, conducted in partnership between the University of Bonn and the Hebrew University of Jerusalem, found low-doses of cannabis improved the memory and increased nerve cell links in older subjects.

The treatment of Alzheimer’s is a lucrative market opportunity, and pharma companies operating in that space are experiencing significant valuations. Anavex Life Sciences, which currently has a candidate in a phase IIa clinical trial for Alzheimer’s disease, has a market cap of around $179 million.

For more information about India Globalization Capital and its groundbreaking phytocannabinoid therapies for Alzheimer’s and other diseases, visit www.IGCInc.us

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Smith-Midland Corporation (SMID) Reports 11.4% Jump in Sales, 69.9% Boost in Net Income for Quarter Ended June 30, 2017

• The precast concrete manufacturer, for the half ended the same date, recorded a 14.1% rise in revenues and a 377% spike in net income
• Safety barrier project in Northern Virginia has SMID working at full capacity seven days a week to meet deadlines
• Company has backlog of $30.2 million, optimistic about profitable performance in 2018

Smith-Midland Corporation (OTCQX: SMID), a precast concrete manufacturer, has announced (http://dtn.fm/Rr9pC) an 11.4% jump in sales for the quarter ended June 30, 2017, and a 69.9% increase in net income. Sales rose to $10.7 million for the quarter, compared to $9.6 million for the same period last year. In the most recent quarter, net income increased to $711,653, compared to $418,924 the same period in 2016.

For the six months ended June 30, 2017, the company generated revenues of $20.2 million, 14.1% higher than the $17.7 million during the same period a year ago. Net income rose to $1,568,854, a 377% jump from $329,148 during the same period the prior year. In its SEC 10-Q filing of August 10, 2017 (http://dtn.fm/XMP5g), the company attributed the gains to a lower cost of goods and increases in sales of high margin products.

Smith-Midland, based in Midland, Virginia, is a precast concrete company which specializes in producing, renting, licensing and selling products for the construction, utilities and transportation industries.

In a news release, Rodney Smith, chairman and chief executive officer, said, “Smith-Midland’s earnings continue to demonstrate our ability to generate profitable returns on a quarter by quarter basis. Lean process improvements and our commitment to customer satisfaction have helped drive quality performance to the bottom line results. With an increase in the current backlog to $30.2 million, the company is well positioned to continue its profitability in 2018.”

He added that Smith-Midland has a purchase order for the safety barrier on the I-395 high occupancy toll lane project in Northern Virginia, as a result the company is working seven days a week to meet the delivery dates required within the contract. He also noted that Smith-Midland is actively bidding for other large safety projects, as well as highway safety wall projects.

For more information, visit the company’s website at www.SmithMidland.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

India Globalization Capital, Inc. (NYSE: IGC) Focuses on Building Phytocannabinoid-based Pharmaceutical Portfolio

• Core operations transitioned to phytocannabinoid-based therapies
• Four trial candidates targeting chronic pain, Alzheimer’s and other conditions
• Unique approach combining existing therapies with cannabinoids

India Globalization Capital, Inc. (NYSE MKT: IGC) is developing disruptive new pharmaceutical therapies to fight a variety of ailments. Currently, the Maryland-based corporation has a pipeline of cannabis-based combination candidates under development to treat Alzheimer’s disease, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy. Supporting this effort, the company has put together a robust intellectual property (IP) portfolio. IGC intends nothing less than to become a leading specialty provider of phytocannabinoid-based pharmaceuticals and complimentary alternative medicine (CAM) nutraceutical products. Operating in the world’s fastest growing industry (cannabis) with its novel ‘something old, something new’ approach, IGC could soon expect its valuation to rise in line with peers like Corbus Pharmaceuticals (NASDAQ: CRBP), Anavex Life Sciences (NASDAQ: AVXL) and Zynerba Pharmaceuticals (NASDAQ: ZYNE).

IGC recently disposed of its low-margin iron ore and electronic trading businesses. With that divestment, the company is now focused on its long-term goal of becoming a heavyweight in the cannabis space. To achieve its objective of being a major player of cannabinoid combination therapies, IGC is actively engaged in planning the development pathways for its four product candidates.

IGC-501 heads IGC’s quartet of pipeline candidates. In September 2015, the company filed a Patent Cooperation Treaty (PCT) application for the therapy, which addresses neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. At present, such indications tend to be treated with opioids, which are notoriously addictive. However, the alarming rise and devastating effects of opioid abuse are driving the search for less pernicious alternatives. In the U.S. alone, this presents a market opportunity of around $25 billion.

A PCT filing has also been made for IGC-502, designed to treat canine seizures, which affect about five percent of dogs. Additionally, in August 2016, the company filed for a therapy to treat cachexia, which it has designated IGC-504. Also known as wasting syndrome, cachexia affects about 1.3 million in the U.S. It is a condition that’s typically associated with cancer, multiple sclerosis (MS), Parkinson’s, and HIV/AIDS.

In June 2017, IGC announced it had entered into a definitive agreement with the University of South Florida making IGC the exclusive licensee of the U.S. patent filing entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” This agreement gives IGC a way to enter a huge market for what has been called ‘America’s most expensive disease.’ For 2017, Medicare and Medicaid expenditures for treating Alzheimer’s are expected to reach $175 billion. Currently, over 5.3 million Americans suffer from the condition, and that number is expected to double over the next 20 years.

The drug candidate IGC-ADI explores an alternative way delta 9-tetrahydrocannabinol (THC) interacts with the human body. Several pathways have already been identified, including binding to the CB1 receptor, anti-oxidative effects, and others, but IGC-ADI works through a different molecular pathway that allows low doses of THC to bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which causes the cognitive decline that results in Alzheimer’s disease. If approved, this patent will give IGC a significant proprietary interest in a unique way to treat Alzheimer’s disease. THC is the psychotropic phytocannabinoid mainly responsible for the ‘high’ of cannabis, although, it must be noted, other cannabinoids such as cannabinol (CBN) and tetrahydrocannabivarin (THCV) are psychotropic. The treatment of Alzheimer’s is a lucrative market opportunity, and pharma companies operating in that space are experiencing significant valuations. Anavex Life Sciences, which currently has a candidate in a Phase IIa clinical trial for Alzheimer’s disease, has a market cap of around $179 million.

The same is true of companies developing cannabinoid-based treatments. Corbus Pharmaceuticals, which presently has programs assessing its oral endocannabinoid-mimetic drug candidate for treating a variety of ailments, has a current market cap of around $310 million, and Zynerba, which is also developing synthetic cannabinoids, has a market cap of about $235 million at present. IGC, trading presently at $0.40, has a market cap of about $12 million, a valuation that is unlikely to stay that low for long.

For more information, visit the company’s website at www.IGCInc.us

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Reports Financial Results for Quarter Ended June 30, 2017

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced its financial results for the quarter ended June 30, 2017. “During the quarter, we secured an IP licensing agreement from the University of South Florida addressing a potential treatment for Alzheimer’s disease,” Ram Mukunda, CEO of IGC, stated in the news release. “This patent filing claims discovery of a new pathway: low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is what occurs in Alzheimer’s disease and causes cognitive decline. IGC expects to release mouse data showing that this pathway and therapy have possible blockbuster potential in treating Alzheimer’s disease. We expect to take this exciting treatment to human medical trials as soon as possible.” IGC reported total revenue of $52,926 for the three-month period, down from $288,493 during the comparable period of 2016. The company attributed this decrease to a corporate mandate to extricate IGC from its electronic and iron ore trading business and focus management on medical cannabis therapies.

To view the full press release, visit http://dtn.fm/ocXN6

About IGC

India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland. For more information visit www.igcinc.us

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Bridges Gap Between China’s Tech-Savvy New Consumer Class and Brick-and-Mortar Businesses

Catering to China’s up-and-coming, tech-savvy consumer class, Moxian, Inc. (NASDAQ: MOXC) is building a crucial bridge between e-commerce and brick-and-mortar retail, providing small- and medium-sized businesses with state-of-the-art turnkey solutions to help them harness Web searches and convert them into foot traffic. Moxian’s innovative and socially interactive online platforms and mobile apps are free to consumers, and they are helping move China’s consumers from online views to in-store retail purchases.

“Moxian’s seductive social network integrates social media and business into a single platform that offers products, features and services that appeal to consumers, keeps them engaged and encourages them to refer new customers. The company’s ingenious online platforms and mobile applications, the Moxian+ User app and the Moxian+ Business app, allow businesses to interface with both new and existing customers. These online interactions provide each business the data to analyze consumer likes, dislikes and trends. Moxian’s platforms provide businesses the ability to create, manage and promote individualized customer loyalty programs, targeted advertising campaigns and special promotions. These interactions between users and Moxian’s merchant clients drive retail traffic into the brick and mortar locations and give merchant clients the ability to study consumer behavior and custom-tailor offerings to consumers.”

To view the full article, visit http://dtn.fm/rf8E5

About Moxian, Inc.

Founded in 2013 in Shenzhen, China with branch offices in Beijing, Malaysia, and Hong Kong, Moxian, Inc. is an offline-to-online (O2O) integrated platform operator. The Company’s “Moxian+” mobile App platform connects Users to Merchant Clients through games, rewards and social events that they enjoy and in return, Users provide valuable information that Merchant Clients can use to effectively promote products and services offered at their brick and mortar stores. More information about the Company can be found at www.moxian.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Monaker Group, Inc. (MKGI) Raises $3M to Strengthen Booking Engine as It Prepares for Uplisting to NASDAQ

• Booking engine as a B2B product set to drive growth
• NASDAQ listing in sight
• Fresh capital injection of $3 million

With the completion of its proprietary booking engine late last year, Monaker Group, Inc. (OTCQB: MKGI) has moved closer to realizing its motto: Travel Made Easy. Now the technology-driven travel company is intensifying its focus on delivering innovation to the alternative lodging rental (ALR) market and, to do so, has bolstered its balance sheet. The company has closed a round of financing with institutional and accredited investors (http://dtn.fm/i2DGk). The funds are earmarked to expand the B2B white label potential of the booking engine and to get the company ready for a listing on the NASDAQ.

Booking engines are the latest iteration by the travel industry to increase access and choice to consumers. They represent the current stage of developments that began in the post-WWII era, when American Airlines (AA) developed the industry’s first automated booking system. Its esoteric name, “Electromechanical Reservisor” (ER), might have puzzled the average traveler if he were allowed access to it, but he was not. Neither were travel agents. Only AA’s airline personnel could access the ER. The airline followed up the ER system, in 1953, with the tongue-twisting Semi-Automatic Business Research Environment reservation system (SABRE).

AA’s success in the reservation business meant that other airlines needed to follow suit to remain competitive. As a result, United Airlines launched Apollo; Delta Airlines came up with DATAS; and Trans World Airlines responded with PARS. These were all proprietary, silo systems, owned and used exclusively by the airlines that developed them, and they were not linked to each other.

By the 1970s, airlines were seeing the advantages of allowing travel agents access to their systems. As a result, the in-house reservation systems morphed into what became known as computer reservation systems (CRS), through which travel agents could query and make reservations. Soon, third party entities hit on the idea of linking separate computer reservation systems, and global distribution systems (GDS) were born. GDS offered travel agents access to the inventory of all the main airlines. Now that agents were part and parcel of the network, the obvious next step was to offer the traveler himself access through a booking engine.

Through a booking engine, a would-be traveler can specify his or her travel requirements such as point of departure, departure date, destination, return date and class of travel. In response, the booking engine will offer airline seats, hotel rooms, alternative accommodation and a variety of related offerings that fit the bill. This is definitely travel made easy.

Monaker expects that most of its growth in the future will come from offering its booking engine as a B2B white label “Alternative Lodging” “Vacation Rental” product to established providers, such as online travel agencies (OTAs) and cruise providers, particularly since it offers “Instant Booking”. Instant Booking allows travelers to initiate a booking and receive an instant confirmation.

Monaker recently completed a private placement of equity with a group of institutional and accredited individual investors for gross proceeds of $3 million. Certain insiders and board members also participated in the offering, representing $635,000, or approximately 21 percent of the offered amount. Part of the proceeds will go toward further development of its booking engine, which forms the core of Monaker’s alternative lodging rental platform. The fresh capital will also facilitate the company’s efforts to be listed on the NASDAQ, which are presently underway.

For more information, visit the company’s website at www.MonakerGroup.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Subsidiary Launches Payment Acceptance Module for Four Popular Instant Messenger Apps

Global financial technology and value-added solutions group Net Element, Inc. (NASDAQ: NETE) this morning announced that its PayOnline subsidiary has launched a payment acceptance module for four popular instant messenger applications: Telegram, Viber, Facebook and VK. Made possible through a collaboration with Botmother, PayOnline’s Instant Payments Module is designed to help the company access a rapidly growing market of instant messaging users. “Chat-bots can be created for different purposes: to reduce the cost of customer support, improve corporate image or to increase sales… We are glad that our colleagues at PayOnline decided to offer their customers such a service using our designer platform,” Sergey Budyakov, one of the creators of the Botmother platform, stated in the news release. “We are ready to adapt and are confident that our design will be suitable for most bot platforms of the future – along with payments via PayOnline.” As noted in the news release, the instant messaging market is currently in a period of unprecedented growth, with a user base that’s expected to increase from over 3.2 billion users in 2016 to over 4.1 billion users by the end of 2020, according to The Radicati Group.

To view the full press release, visit http://dtn.fm/5k8E2

About Net Element

Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the US and selected emerging markets. In the US it aims to grow transactional revenue by innovating SME productivity services such as its cloud based, restaurant and retail point-of-sale solution Aptito. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions such as UAE, Kazakhstan, Kyrgyzstan and Azerbaijan where initiatives have been recently launched. Net Element was named in 2016 by South Florida Business Journal as one of the fastest growing technology companies. Further information is available at www.netelement.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

India Globalization Capital (NYSE: IGC) Shows Potential for Strong Market Valuation Growth

• India Globalization Capital recently acquired exclusive patent rights for the use of low-dose THC as a potential therapeutic agent for Alzheimer’s disease
• No other publicly traded cannabis pharmaceutical company has a patent filing for a potential Alzheimer’s treatment
• Costs associated with Alzheimer’s disease top $236 billion in the U.S. and $600 billion globally

India Globalization Capital, Inc. (NYSE MKT: IGC), a Maryland-based company, is currently preparing four products for medical trials, including Hyalolex for the treatment of Alzheimer’s disease. Alzheimer’s is a fatal, progressive brain disease that slowly destroys memory and thinking.

Alzheimer’s is the leading cause of dementia and the third-leading cause of death in the U.S. Treatment outlooks have been bleak, as there is currently no cure, no way to prevent the disease, and no long-term treatment for the disease. However, India Globalization Capital may well improve the outlook for Alzheimer’s patients with a novel cannabis-based pharmaceutical therapy.

From an investment standpoint, IGC’s potential for market valuation growth is striking due to the size of the market for a successful Alzheimer’s treatment. Other companies in the cannabis space and also those focused on treatments for Alzheimer’s are valued in the hundreds of millions – and even billions – of dollars.

A definitive licensing agreement with the University of South Florida makes IGC the exclusive licensee of a U.S. patent filing titled, “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” The patent filing targets amyloid beta plaques, believed to be the cause of Alzheimer’s disease. The patent asserts that a newly discovered pathway allows low doses of THC to bind to amyloid beta plaques and keep them from accumulating on neurons, thus impacting the disease’s notorious cognitive decline. Be sure to view the CNN video on IGC’s website for additional information- http://www.igcinc.us/alzheimers-disease-1.

India Globalization Capital is preparing other phytocannabinoid-based pharmaceutical therapies for medical trials that target nausea and vomiting in AIDS and cancer patients; sleep disorders, anxiety and dyskinesia in Parkinson’s patients; and seizures in dogs and cats.

In addition, the company is developing treatments aimed at neuropathic and cancer pain, epilepsy, PTSD, end-of-life supportive care, and therapies for chronic neurological and cancer diagnoses.

India Globalization Capital is a first mover in the area of cannabis-based combination therapy and has filed for six patents in large market treatments including pain, eating disorders and epilepsy. Patents have been filed for a pain medication in the U.S., Canada and Europe, and upcoming filings include therapies aimed at PTSD, depression, Alzheimer’s and Parkinson’s disease.

For more information, visit www.IGCInc.us

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Cogint, Inc.’s (NASDAQ: COGT) Sales Jump 29% to $53 Million For 2Q2017

• Adjusted EBITDA increases 54% in quarter to $4.8 million
• Cogint’s information services segment revenues rose 39% in quarter
• Pay Per Call, a new product, generated $1.5 million in additional sales in 2Q2017, as wide range of ‘vertical’ clients adopted it

Cogint, Inc. (NASDAQ: COGT) revenues reached $53 million for the second quarter ended June 30, 2017, a 29% rise as compared to the same period in 2016. Sales for the first half of 2017 ended the same date increased to $103.8 million, also a 29% spike from the prior year, the company announced (http://dtn.fm/aq9Ll).

Cogint is a cloud-based data analytics company with proprietary algorithm technology platforms, such as CORE™ and Agile Audience Engine™, which are applicable to a multitude of industries. The company’s goal is to achieve return-on-investment driven results for clients. The firm uses data fusion and customized analytics to help clients manage risk, identify fraud and abuse, collect debts and acquire new customers.

In a news release, Derek Dubner, chief executive officer of Cogint, said, “We delivered a very strong quarter with revenues of $53 million, up 29% versus the second quarter of 2016, and adjusted EBITDA of $4.8 million, up 54%, driven by enterprise-wide adoption of our products and solutions. Given our innovative-driven product roadmap and the increasing momentum we experienced throughout the quarter, we are very optimistic about the second half of 2017.”

Key to the gains were a 39% jump in sales within information services, a 24% boost in performance marketing and revenue from its new Pay Per Call ad format, which was introduced in December 2016 and generated $1.5 million in additional sales in 2Q2017.

CORE™ is the company’s own next-generation data fusion platform, applicable to a variety of industries. These range from insurance and financial services companies to law enforcement, health care, law firms, government and others.

The Agile Audience Engine™ assists retailers, brands and marketers with customer identification on a massive scale. It targets consumers through personal identification information for the packaged goods, financial services and entertainment industries, among others. What helps make Cogint unique in this sector is its high 80% use of mobile devices for consumer interaction.

For more information, visit the company website at www.Cogint.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Booming US E-commerce Market Offering Net Element (NASDAQ: NETE) Ample Opportunities for Growth

• Company’s PayOnline provides flexible, integrated payment solutions for e-commerce sector
• Platform matches almost all native systems, offline and online, including on mobile
• Online sales reached $395 billion in 2016, remaining a primary growth driver in the overall retail industry

The U.S. e-commerce market is rapidly expanding, as consumers benefit from a growing number of channels for online ordering, driven by a strong preference of younger generations to make their purchases online. Internet sales reached roughly $395 billion in 2016, accounting for 11.7 percent of total retail sales reported nationwide last year, according to Department of Commerce data (http://dtn.fm/7iagU). The trend continued into 2017, with online retail sales reaching $105.7 billion in the first quarter. This fast-growing market offers ample investment opportunities to online payment solution providers such as Net Element, Inc. (NASDAQ: NETE) and its subsidiary PayOnline, an innovative and flexible payment processing platform.

Online retail sales in the United States grew at an accelerated rate in 2016 compared to previous years. With a 15.6 percent increase reported, e-commerce accounted for nearly 42 percent of all U.S. retail market growth last year. For comparison, total retail sales in 2016 were $3.375 trillion, factoring out sales in restaurants and bars, as well as items that are not usually purchased online, such as automobiles, fuel, etc. Most of the e-commerce market share is still held by Amazon.com, Inc. (NASDAQ: AMZN), which remains leader when it comes to online sales and a favorite brand among U.S. consumers. The internet giant reported transactions of $147 billion in 2016, which is more than 31 percent higher than the previous year.

Mobile purchases are leading the way when it comes to the growth of the e-commerce sector, with almost half of the digital retail traffic happening on mobile, according to Business Insider data (http://dtn.fm/QZnV0). But the traffic increase does not translate into actual purchases, with consumers preferring to use desktop computers rather than their smartphones for online orders. The volume of mobile traffic, however, presents a major opportunity for retailers, as mobile allows consumers and vendors to communicate more effectively and more frequently. With the right tools and software, mobile payments could grow exponentially, helping expand the digital sales market further.

This is where global financial technology group Net Element’s PayOnline platform comes in. Having just entered the U.S. e-commerce market, the PayOnline subsidiary is one of the most versatile global online payment solutions in the industry, leveraging its parent company’s experience with omni-channel electronic payments acceptance solutions that include e-commerce, point-of-sale and mobile devices.

Providing flexible high-tech payment solutions to more than 3,000 companies in markets such as Eastern and Western Europe, Central Asia and the Commonwealth of Independent States, PayOnline is designed to allow retailers to expand their business by offering customers as many payment options as possible. In addition, the platform is developer-friendly, with its API and SDK allowing merchants to easily integrate it with their native systems, both offline and online, including via mobile apps.

PayOnline supports more than 100 payment methods in as many currencies, in addition to credit card acceptance, and it is certified with most payment processors in the United States and globally. With industry-leading security features making the system a safe and viable option for all retailers, PayOnline also offers easy e-commerce and CMS integration, already being available on the most popular platforms.

Net Element expects the fully integrated payment solution to be as successful in the U.S. as it has been abroad, allowing it to generate significant revenue for the company. The successful implementation of PayOnline on the local e-commerce market will expand the company’s global reach and position Net Element as a leading provider of state-of-the-art, high-tech payment solutions for multiple verticals.

For more information, visit the company’s website at www.NetElement.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Moxian, Inc. (NASDAQ: MOXC) Changes Venue and Record Date for its 2017 General Meeting of Stockholders

• Meeting will be at Swissotel in Beijing, China, on September 29 at 10:00 a.m. local time in order to accommodate more shareholders; the new record date is August 30, 2017
• SeeThruEquity projects that Moxian revenues will reach $24.1 million by FY2018
• Moxian is targeting a Chinese mobile market of 1.3 billion people, the world’s largest

Moxian, Inc. (NASDAQ: MOXC) has changed both its venue and record date for its 2017 general meeting of stockholders. The new record date is August 30, 2017, and the location of the meeting has been moved to the Swissotel in Beijing, China, in the Hong Kong Macau Center.

The meeting’s time and date remain unchanged. It will held on September 29 at 10 a.m. local time, which is 10 p.m. ET on September 28.

Moxian is headquartered in Shenzhen, China, with offices in Beijing, Malaysia and Hong Kong. It is an online-to-offline (O2O) integrated platform operator. The company is converting its unpaid platforms to paid. It has the Moxian+ Business mobile app, which generates revenue by connecting consumers to small- and medium-sized market enterprises (SMEs) through social platforms, games and rewards available through earned Mo-Points. Client merchants can then learn more about consumers, completing online sales via their own brick-and-mortar offline stores.

The company generates revenues via subscription and licensing income, selling premium consumer data to merchant clients, advertising, and a percentage of all transactions. Moxian already has 31,600 merchants on Moxian+ Business. By mining data gleaned through analytics, Moxian enables vendor clients to promote and market their products.

To consumers, it offers the Moxian+ User app. It has some 300,000 registered users on this platform, which is also being converted to paid, and offers social events, contests and prizes. The company also has the proprietary Mo-Talk, a voice-chat service on both apps, enabling client merchants and consumers to interact.

SeeThruEquity estimates that the company will generate revenues of $24.1 million by FY2018 (http://dtn.fm/Po0qP). Moxian is targeting a Chinese mobile phone market of 1.3 billion people, the research firm notes, quoting China’s Ministry of Industry and Technology statistics. That market is the largest of its kind in the world.

For more information, visit the company’s website at www.Moxian.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Monaker Group, Inc. (MKGI) Announces Completion of $3 Million Private Placement ahead of Planned Nasdaq Uplisting

Travel and technology company Monaker Group, Inc. (OTCQB: MKGI) this morning announced the completion of its previously detailed private placement equity financing with a group of institutional and accredited individual investors for gross proceeds of $3 million. Certain insiders and board members also participated in the offering, representing $635,000, or approximately 21 percent of the offering amount. “This new capital provides us the means to further strengthen our B2B alternative lodging rental platform for mainstream travel companies eager to enter the vacation rental space, as well as prepare us for an up listing to the Nasdaq Capital Market,” Bill Kerby, CEO of Monaker Group, noted in the news release. “We believe this successful funding reflects the confidence of institutional investors in our unique business model and recognition of how our customizable booking platform — the first to offer 1.4 million instantly-bookable alternative lodging properties — will be a true game changer for the travel industry.” Monaker intends to use proceeds from this placement to expand its technology division and alternative lodging rentals offerings, as well as for general corporate purposes.

To view the full press release, visit http://dtn.fm/vWgj8

About Monaker

Monaker Group is a technology-driven travel company focused on delivering innovation to alternative lodging rentals (ALR) market. The Monaker Booking Engine (MBE) delivers instant booking of more than 1.2 million vacation rental homes, villas, chalets, apartments, condos and castles. MBE offers travel distributors and agencies an industry-first: a customizable instant booking platform for ALR. Monaker’s NextTrip.com B2C website, also powered by MBE, is the first to offer significant instantly-bookable ALR products along with mainstream travel products and services all on a single site. NextTrip also features rich content, imagery and high-quality video to enhance a traveler’s booking experience and assist in the search, decision and buying process for both individuals and groups. For more information, visit www.monakergroup.com or www.nexttrip.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Qualstar Corp. (NASDAQ: QBAK) is “One to Watch”

Bright Future for LTO Tape Tech, QBAK a Sector Pioneer
N2Power Upside Bullish Amid Burgeoning Gaming Market
12 Months of Positive Cash Flow, Solid Long-Term Fundamentals
Qualstar is one of the oldest names in data storage, with a track record stretching back to the company’s founding in 1984 as one of the first tape drive developers for PC and workstations. Having developed Linear Tape-Open (LTO) technology alongside industry giants HP (NYSE: HPQ) and IBM (NYSE: IBM) in 1998, QBAK is a storied outfit that famously helped offer a clear and viable choice in earlier days of the computing revolution when there was a great deal of confusion due to an increasingly complex tape storage market. And the company is now also known for their N2Power subsidiary’s superbly designed, highly efficient, power-dense, and ultra-small power supply units (PSUs), which are utilized in a wide variety of equipment across numerous industries.

LTO Tape, a Potential Answer to Tightening Cloud Storage Margins

Now, investors may not be aware of this, what with all the retail consumer-directed ballyhoo over the latest solid state drives, but seemingly ancient tape drive technology is actually pretty compelling. Particularly when it comes to handling archival data and backups, where the latest generation of LTO-7 drives have proven themselves in independent testing to be excellent solutions. SSG-NOW ran some tests in March on Ultrium cartridge (LTO tape specification optimized for capacity and performance) based LTO-7 tapes, finding them not only ready for use in a productionenvironment, but easy to use thanks to the Linear Tape File System (LTFS) making them appear as just another mounted drive. Generation 8 of LTO Ultrium is slated to more than double storage space to 32 terabytes, with more than a 57 percent increase in speed, up to 1,180 megabytes per second.

Of the big three industrial-scale cloud storage players, Google (NASDAQ: GOOGL; GOOG) is the only one to really talk publicly about using tape in its storage architecture. Microsoft (NASDAQ: MSFT) often touts the tech, but is very hush-hush about its Azure platform build. And Amazon (NASDAQ: AMZN) is apparently still living in the 90’s, when tape first fell out of favor, largely due to the emergence of cheaper and bigger disk drives, as well as problems associated with the terrible backup software they had back then.

The truth is that LTO, especially given the future roadmap for the tech (size and speed nearly doubling each generation), represents an ideal solution when it comes to reliability and performance in archival, backup, and storage tasks. Especially amid the rise of big data. And LTO is a solution which is also low-cost, preserving and enhancing the margins of the cloud business model, as we leap into the abyss of requiring zettabytes (one sextillion bytes) of storage in order to handle all the data we are producing. The increasingly rapid emergence of a world of connected, intelligent devices (Internet of Things, or IoT), and the big data analytics necessarily associated therewith, will put increasing pressure on cloud vendors to migrate into high-performance, low-cost solutions like tape.

QBAK Superbly Positioned to Exploit Underlying Market Dynamics

Not only do the kinds of tape solutions which Qualstar is known for have the power to save the economics of the post-zettabyte cloud model, these tape-based storage solutions also happen to represent easy access to an ideal cloud seeding workaround. This allows companies to bypass slow, contemporary networks when it comes to getting their data to the cloud. Due to an increasingly prevalent method where data is mirrored onto physical media like a tape drive and then physically sent to the cloud storage company’s server farm, cloud seeding via couriers is quickly becoming standard operating procedure for many.

Notably, there are several other key factors that set tape storage technology out as clear winner moving forward. Native write speeds of 300 MBps or greater (SSG-NOW was clocking rates of 750 MBps on readily-compressible documents like Word files and PDFs) is one of the greatest reasons. The Linear Tape File System’s (LTFS) super easy backup and restore workflow is another key aspect, which is inherently similar to disk-to-disk mirroring, but without the need for special backup software.

Considering $203 billion plus estimates for the big data and analytics market by 2020 (a nearly 12 percent CAGR), Simi Valley-headquartered QBAK looks to be in an extremely favorable position. Qualstar’s Simply Reliable™ XLS architecture is one of the most attractive solutions on the market today for growing data centers, due to proven flexibility, modularity, and reliability. Using self-contained, standalone LRMs (library resource modules) as the core, this architecture is also easily expandable for big capacity via MEMs (memory expansion modules).

The strong data management and storage offerings from this company, like the XLS-89000 MEM unit, will no doubt see Qualstar slicing off an ever larger slice of a growing pie, as cloud vendors awaken to the performance, scalability and cost benefits of such LTO architectures. The XLS-89000 boasts an incredible 16.13 petabytes of storage at maximum compression using LTO-7 (6.45 PB native), can hold 1,075 tape cartridges, and can be easily “daisy chained” with either type of XLS enterprise library system (XLS‑832700 or XLS‑8161100). This allows for field expandability up to 7,500 cartridges.

It is important for investors to understand how this easy extensibility and scalability translates directly into ease of use for operators, making these well-thought-out designs as intuitive, as they are powerful. QBAK’s patented Compass Architecture carousel technology allows for ridiculously high-density storage of 758 terabytes (uncompressed) per square foot, while still enabling the robotic tape handler to function in a gentle-motion profile, leading to improved reliability from this vital system. Whether a company is just starting out and wants a single, automated, high-capacity rack mountable tape library like the RLS-8350 (expandable by up to 8x via RLS-85120 modules), or is ready to enter the big leagues with a fully-expanded XLS setup, Qualstar is a one-stop shop for robust storage.

N2Power a Potential Sleeper Hit

The increasing probability of data ending up on tape is an important trend for investors following the growth of the data market – and it holds true whether a company is doing backup and archival in-house, or handing off to a cloud service. This is very bullish for QBAK’s enterprise library system business, but the company’s N2Power subsidiary may hold even more promise. N2Power has developed a very healthy market for the company’s industry-spanning array of ultra-small, highly efficient power supplies, which feature some of the highest power densities on the market. The diminutive power supplies are green by design, with up to a 93 percent efficiency rating, a lower heat generation profile, and most units require little or no forced air cooling.

With a strong footing in various markets like gaming, IT (both PSUs and enclosures), medical, light industrial and high-power equipment, N2Power has accrued quite the reputation for its beefy little PSUs (power supply units). Leading to a strong foundational market position and deals like the recently announced (July 25) $0.6 million the company landed in multiple orders for PSUs set to ship over the next five months or so, from an existing, prestigious gaming industry customer. The global casino gaming market is set to expand at 10.16 percent through 2021 according to a recent report from Research and Markets. The US casino gaming market represents the lion’s share of the space and is set to hit $93 billion by 2020. And the broader global digital gaming market (minus mobile) is around $62.8 billion this year and is on-track to grow as a whole by around 6.2 percent CAGR through 2020, on the strength of continued user adoption rates, and factors such as eSports and VR.

This is a great cultural backdrop and market environment for QBAK’s N2Power, which has established itself as a favored provider of feature-rich gaming PSUs to a variety of customers, ranging from some of the top casino gaming and ATM machine developers, to LED/lighting, and other applications. The ultra-dense, efficient power supplies N2Power provides to OEM designers are much sought after, not only because they reduce thermal load and cooling requirements, which is cheaper on energy, but also because the greater density frees up crucial machine real estate to make more room for other components. N2Power makes some of the tiniest, most reliable 125W to 500W AC-DC PSUs in existence today.

Strong Bottom Line Makes a Nice End Cap

It’s little wonder then that QBAK’s Q2 results showed YoY net income up 116 percent, in part on strong sales growth, as well as product expansion in the N2Power unit. With a strong balance sheet and no debt, such data points as the 6.5 and 6.9 percent increases (respectively) in gross profit margins for the three- and six-month periods (compared to the same period in 2016) are something which should really stand out to investors as a sign of the company’s fitness. Even before taking note of a 22.8 percent reduction in operating expenses over the six month period.

Take a closer look, visit http://www.qualstar.com/index.php

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

ARCA Biopharma, Inc. (NASDAQ: ABIO) Brings Precision Medicine Closer to Reality

• Drug candidate for top cause of death in the United States
• Genetically-targeted therapy increases chances of recovery
• Interim efficacy analysis soon to be conducted by the Data Safety Monitoring Board

Atrial fibrillation affects up to six million people in the U.S. The condition, if untreated, can lead to blood clots, stroke, heart failure and other heart-related complications, but many medications currently in use to treat it come with worrying side effects, perhaps because of their one-size-fits-all approach. In an effort to mitigate the unwanted, unintended action of these agents, ARCA Biopharma, Inc. (NASDAQ: ABIO) is applying a precision medicine approach, developing genetically-targeted therapies for cardiovascular diseases, as it works to bring its lead candidate for atrial fibrillation, Gencaro™, to market. The company believes that by tailoring medical treatment to the individual genetic characteristics of patients, more effective therapies will be enabled, patient outcomes will be improved and health care costs will go down.

Atrial fibrillation (AFib) is the most common kind of heart arrhythmia, a condition where the heart beats too fast, too slow, or in an irregular fashion. In a heart suffering from AFib, the regular pumping action of its upper chambers, the atria, is impaired. As a result, blood flow to the lower chambers, the ventricles, is impeded. AFib increases a person’s risk for stroke by four to five times compared with people who do not have it, and strokes caused by complications from AFib tend to be more severe than strokes with other underlying causes. AFib causes 15%–20% of ischemic strokes, which occur when blood flow to the brain is blocked by a clot or by fatty deposits called plaque in the blood vessel lining.

According to the Centers for Disease Control and Prevention (http://dtn.fm/sCD06), “more than 750,000 hospitalizations occur each year because of AFib… (and) the condition contributes to an estimated 130,000 deaths each year. (In addition), the death rate from AFib as the primary or a contributing cause of death has been rising for more than two decades.” AFib costs the United States about $6 billion each year, and medical costs for people who have AFib are about $8,705 higher per year than for people who do not have AFib.

Current treatments for AFib include drugs for heart rate control, drugs for heart rhythm control, and blood thinners. These medication, however, give rise to a plethora of side effects, including breast enlargement, diarrhea, low blood pressure, and heart failure, as well as psychological problems. One class of drugs that controls heart rate is known as beta-blockers; drugs of this type work by reducing heart rate, an example of which is ARCA’s lead candidate, Gencaro.

Gencaro (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator, now under evaluation in a clinical trial for the treatment and prevention of recurrent AFib in heart failure patients with reduced left ventricular ejection fraction, or HFREF. The company believes that Gencaro’s mechanism of action (MOA) differs from other beta-blockers because of its sympatholytic (norepinephrine lowering) and inverse agonism (inactivation of constitutively active receptors) properties. Genetic variations in receptors in the cardiovascular system of the general population vary, and these variations are thought to be a factor in how well patients respond to treatment. With Gencaro, ARCA has developed a formulation which interacts positively with a genotype, beta-1 389 arginine homozygous, found in approximately 50 percent of the U.S. population. Consequently, a Gencaro regimen promises a reduced range of side effects for a larger population of patients.

In June 2017, ARCA announced database lock for the GENETIC-AF interim efficacy analysis to be conducted by the trial Data Safety Monitoring Board (DSMB). Locking or closing a database ensures that no unauthorized or unintentional changes are made after the final data entry, check-up, and analysis. GENETIC-AF is a phase 2B/3 double-blind, clinical superiority trial comparing the safety and efficacy of Gencaro to an approved drug, TOPROL-XL, for the treatment and prevention of recurrent AFib in heart failure patients with reduced left ventricular ejection fraction (HFrEF). The company expects to announce the DSMB’s recommendation based on this interim analysis in August 2017. The Gencaro development program was previously granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

For more information, please visit www.ARCABio.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Net Element, Inc. (NASDAQ: NETE) Proposes a Reverse Split of its Common Stock to Increase Valuation

• Proxy to shareholders seeks a reduction in Net Element’s common shares from 400 million to 100 million
• NETE reaches 30-month term stock purchase agreement with Cobblestone Partners
• Sets August 10 meeting with NASDAQ to present plan for listing compliance

Net Element, Inc. (NASDAQ: NETE) has proposed to shareholders a reverse split of its common stock at a ratio of between 1-for-10 and 1-for-30 on the proxy at its annual meeting in 2017 (http://dtn.fm/mod3S). It also plans to put to a vote of shareholders a reduction in common stock from 400 million shares to 100 million shares in the hope that fewer shares will result in an increase in the market price of its common shares.

NETE is a cloud-based global financial company that accepts electronic payments in an omni-channel environment. It processes payments in what is becoming a cashless economy at point-of-sale and on mobile devices. It also offers clients management tools in its systems. A Zack’s Research Report (http://dtn.fm/1uNBd) projects that the company will generate revenues of $74.6 million by 2018.

In the SEC filing of the proxy (http://dtn.fm/lIbk9), NETE said that it will appeal the NASDAQ market’s deficiency letter in a meeting on August 10. NETE said the purpose of the reverse stock split amendment is to decrease the number of outstanding shares of common stock and potentially increase the market price of its common stock. A stay of the decision by NASDAQ is in effect pending an appeal by the company.

“The company is considering several paths to regain compliance with the minimum bid price requirement, including, among other things, a reverse stock split,” the company said in the filing.

The proxy also detailed its July 5, 2017, agreement with Cobblestone Partners, LLC, to purchase up to an aggregate of $10 million of NETE’s common stock over the 30-month term of the purchase agreement. Proceeds from the agreement will be used by the company for working capital and general corporate purposes. The proposal, approved by shareholders in the proxy, would permit Cobblestone Partners to buy in excess of 19.99% of NETE’s outstanding shares, as per NASDAQ rules.

In a letter to shareholders (http://dtn.fm/i2aLL), NETE management also said that it has a program of cost cuts that should be realized by the third quarter of 2017.

For more information, visit the company’s website at www.NetElement.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Moxian, Inc. (NASDAQ: MOXC) Taking Initiative on Generational Opportunity

- New Chinese economy has produced new Chinese consumer

- Consumer has pent up demand

- Moxian provides platform to motivate and move consumers to retail outlets


There’s little doubt that economic forces have transformed the Chinese consumer markets. The meteoric rise of middle-class households, a new generation of tech savvy consumers and the powerful pull of e-commerce all promise immense new consumer opportunities in China. A long time in the making, China’s consumer class has arrived.

China’s state run economy has pushed and pulled the country from subsistence agrarians to leading edge high-tech manufacturing with workers and consumers evolving along the way. Over 40 years in the making and with huge pent up demand, the new Chinese consumer class is ready to fully engage the twenty-first century. Technologically astute, the new Chinese consumer is poised to dramatically impact the economy of not only China but also the world. Companies that operate in and cater to this new megalith of consumption stand to be handsomely rewarded.

Moxian, Inc. (NASDAQ: MOXC) caters to and focuses on the new Chinese consumer and, importantly, bridges e-commerce to brick-and-mortar retail. Moxian provides small- and medium-sized brick-and-mortar businesses with cutting-edge turnkey solutions to attract and maintain customers. Free to the consumer, Moxian’s creative and socially interactive online platforms and mobile applications are moving the burgeoning Chinese consumer from online views to retail purchases at Moxian’s brick-and-mortar retail client locations. Moxian’s seductive social network integrates social media and business into a single platform that offers products, features and services that appeal to consumers, keeps them engaged and encourages them to refer new customers.

The company’s ingenious online platforms and mobile applications, the Moxian+ User app and the Moxian+ Business app, allow businesses to interface with both new and existing customers. These online interactions provide each business the data to analyze consumer likes, dislikes and trends. Moxian’s platforms provide businesses the ability to create, manage and promote individualized customer loyalty programs, targeted advertising campaigns and special promotions. These interactions between users and Moxian’s merchant clients drive retail traffic into the brick and mortar locations and give merchant clients the ability to study consumer behavior and custom-tailor offerings to consumers.

Moxian continues to expand its web platform in an effort to entice and draw in consumers to its business clients. The company just announced another strategic partnership with a major high end retailer (http://dtn.fm/NI6qO) that should provide synergies, new products and technologies and open new distribution channels in high-growth markets. “China’s retail industry is going through a major transformation where mobile payments, marketing tools and customer data analytics converge into one single platform, and Shewn is a good example of a nationwide merchant capitalizing on the power of such platform to improve its marketing efficiency,” James Tan, chief executive officer of Moxian, stated in the news release. “With the extension of our powerful Moxian+ mobile App platform to Shewn and its distribution network, we look forward to a mutually beneficial relationship between the two parties in years to come.”

Moxian is taking the initiative to capitalize on what is a generational opportunity, and it appears that the company is positioned to be amply rewarded.

For more information, visit the company’s website at www.Moxian.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Moleculin Biotech (NASDAQ: MBRX) to Begin Preparing Clinical Testing Sites for Leukemia Treatment

- NASDAQ Biotechnology Index up and climbing

- Developing new treatment for acute myeloid leukemia (AML)

- Lead candidate, Annamycin, now at phase II


Since a rising sea lifts all boats, it’s decidedly good news for Moleculin Biotech, Inc. (NASDAQ: MBRX) that the NASDAQ Biotechnology Index (NBI) is enjoying a spring tide. The index has offered a year-to-date return of over 17 percent and seems set to keep climbing. This benign environment gives Moleculin an opportunity to advance work on its leading anti-cancer drug candidates. The company has begun to identify and prepare testing sites in Europe and has already appointed a Lead European Principal Investigator.

Moleculin was featured on Business Insider (http://dtn.fm/8LbO7), in a piece that attributed the rise in the NBI to ‘recent FDA decisions and clinical trial developments’. Moleculin, a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, announced on August 3 that it had selected Bioscience SA (Bioscience), a Polish contract research organization (CRO) to begin identifying and preparing clinical testing sites in Poland for Annamycin. Annamycin is the company’s drug candidate for the treatment of relapsed or refractory acute myeloid leukemia (AML).

AML is a type of blood cancer that usually develops in cells destined to become leukocytes or immune cells. It stunts their development and, consequently, results in a profusion of immature cells. As these immature cells, also known as blast cells, continue to build up, they may find their way into the lymph nodes, the liver, the spleen, the testicles or the brain, with highly deleterious effect.

In 2016, about 21,380 people of all ages (11,960 men and boys and 9,420 women and girls) were diagnosed with AML in the United States, according to Cancer Net (http://dtn.fm/0pGqR). The condition is the second most common type of leukemia diagnosed in adults and children. It is rare for AML to occur before age 45, and the average age at the time of diagnosis is 67 years. However, roughly three-quarters of those who develop it die within five years.

Moleculin’s lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory AML. So far, there are promising indications that Annamycin can circumvent some of the problems encountered in current treatment regimens, such as the risk of cardiotoxity, where treatment drugs damage the heart, and multi-drug resistance. Moleculin also has two active pre-clinical small molecule candidates in the pipeline. The first is directed at modulating hard-to-target cell signaling mechanisms and appears capable of stimulating a patient’s natural immune system while also attacking tumors directly. The second candidate targets the metabolism of tumors and exploits a unique approach for crossing the blood brain barrier for the treatment of glioblastoma and other central nervous system malignancies.

Some of Moleculin’s anti-cancer drug candidates are based on license agreements with The University of Texas System on behalf of the MD Anderson Center. MD Anderson is one of the original three comprehensive cancer centers in the U.S., and, in 2016, was ‘ranked #1 for cancer care in the “Best Hospitals” report published by the U.S. News & World Report.’

For more information, please visit www.Moleculin.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html